Use of myostatin inhibitors and combination therapies
US10946036B2 · kind B2 · utility
4Cited by
7References
22Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 13, 2017 |
| Grant date | Mar 16, 2021 |
| Priority date | — |
| Expiry date | Jun 28, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to the treatment of muscle conditions, such as SMA, with the use of an agent that inhibits myostatin signaling. The disclosure includes combination therapies that include a myostatin inhibitor and a neuronal corrector.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.